Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Markets Are Down. Unlock Undervalued StocksFind Stocks Now

Biogen Inc (BIIB)

NASDAQ
Symbol
Exchange
Currency
BIIBNASDAQUSD
1BIIBMilanEUR
BIIBTradeGateEUR
BIIBFrankfurtEUR
BIIBXetraEUR
BIIBSantiagoUSD
BIIBBuenos AiresARS
BIIB34B3BRL
BIIBViennaEUR
Currency in USD
Disclaimer
194.86
+0.75(+0.39%)
Real-time Data

BIIB Comments

i bought all in. i have time. they can't fight among us.
buy
$ 5B in share repurchase, that's 12% of market cap. Huge huge move
EPS 34,14 WITH P/E 7,82? THIS IS PURE GOLD!
Big miss on top and bottom
There is conflicting information on this app as to whether Biogen beat estimates. Investor.com says yes, but MarketWatch says no - strange?
Check earning report from Biogen.
This will go down becos it beats the forecast...lol.
This is one of the most undervalued stocks in the industry, with robust financials. It generates a handsome $15B in yearly revenues, maintains 50% net margins, boasts 18% return on assets, and has enough cash on hand to wipe out its current debt at any time. What's currently plaguing the company is its anemic growth between 0-6%. While the company can, it should not issue dividends, but rather reinvest in R&D consider a strategic acquisition.
sounds like your average price is 350
One of the risks involved with investing in pharma/biotech is drug failure. However, this is not an uncommon occurrence, which is why most well established companies have other drug candidates in their pipeline. This stock is trading at a P/E of close to 8 which is a joke, while its peers are trading at a P/E of 15. I welcome any dips in the stock to buy additional shares.
Are you asking what my cost basis is, or what my price target is?
Michel Vounatsos CEO he suggested him to help him and he accepted. I congratulate Mr. Trump he is brave and a real Man .
Trump drinks the coctail from Biogen . hahaha. He will test first . He is a real Hero Man.
here its simple Aducanumab FDA approval and we go str8 to 500 or not and we go str8 to 150
here its simple Aducanumab got FDA approval and we go str8 to 500, if not 150.
I don’t think so
I had thought about buying it but I saw that a trial recently stopped http://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/ago202004/47_los/
nasdaq -5%. biogen + 1%. nice hatch
BIIB is almost immune to market downturn, take a look at its behavior in March the whole world was collapsing, BIIB shareholders were happily holding.
One interesting article said that this stock will make a few people instant trillionaires, not sure how, but sure enough, with market cap of 50billions, it can pop to 500billions, 10X of today's price, yes, amazon price 3000
Can u send link please?
Evidently, you spent too much time in high school sniffing Elmer's Glue.
dropped 3% today with no news, if there is no news in the next couple of days, just buy more
jo
Sundial growers next week 1,5 $
I posted on 8th July this stock should be 320
And I bought for 280 USD cople stocks, because I found it attractive as well.
I still see $320+. Holding, long-term.
and even now you see $320+?
What is going on with this stock
It seems that some peers of Buffet with difficulty but remember why they bought these shares 15 years ago for $ 28. But what about Warren himself? )))
It seems that some peers of Buffet with difficulty but remember why they bought these shares 15 years ago for $ 28. But what about Warren himself? )))
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease! Google it
what did I say last week??? Pre market @ 290 and its going above 300
This stock is way undervalued. I believe the price should be between $320 - $350
what's new with this stock
Lost patent jury
...
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.